Immune correlates of vaccine protection against HIV-1 acquisition

Science Translational Medicine

Volumn 7, Issue 310, 2015, Pages

  Corey, Lawrence ^a   Gilbert, Peter B ^a   Tomaras, Georgia D ^b   Haynes, Barton F ^b   Pantaleo, Giuseppe ^c   Fauci, Anthony S ^d  

^a USA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; NEUTRALIZING ANTIBODY; RV144 VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BLOOD LEVEL; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG RESPONSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; INFECTION PREVENTION; INFECTION RISK; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; VACCINATION; VACCINE PRODUCTION; VIRUS ENVELOPE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY;

AIDS VACCINES; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS;

EID: 84945929301     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aac7732     Document Type: Review

References (59)

1. F. Tanser, T. Bärnighausen, E. Grapsa, J. Zaidi, M.-L. Newell, High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 339, 966-971 (2013).
2. A. Pharris, G. Spiteri, T. Noori, A. J. Amato-Gauci, Ten years after Dublin: Principal trends in HIV surveillance in the EU/EEA, 2004 to 2013. Euro Surveill. 19, 20968 (2014).
3. Today's HIV/AIDS Epidemic (Centers for Disease Control and Prevention, Atlanta, GA, 2014).
4. The Gap Report (Joint United Nations Programme on HIV/AIDS, Geneva, 2014).
5. M. I. Johnston, A. S. Fauci, HIV vaccine development-Improving on natural immunity. N. Engl. J. Med. 365, 873-875 (2011).
6. A. S. Fauci, H. D. Marston, Ending AIDS-Is an HIV vaccine necessary? N. Engl. J. Med. 370, 495-498 (2014).
7. S. Rerks-Ngarm, P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. Paris, N. Premsri, C. Namwat, M. de Souza, E. Adams, M. Benenson, S. Gurunathan, J. Tartaglia, J. G. McNeil, D. P. Francis, D. Stablein, D. L. Birx, S. Chunsuttiwat, C. Khamboonruang, P. Thongcharoen, M. L. Robb, N. L. Michael, P. Kunasol, J. H. Kim; MOPH-TAVEG Investigators, Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209-2220 (2009).
8. S. Nitayaphan, P. Pitisuttithum, C. Karnasuta, C. Eamsila, M. de Souza, P. Morgan, V. Polonis, M. Benenson, T. VanCott, S. Ratto-Kim, J. Kim, D. Thapinta, R. Garner, V. Bussaratid, P. Singharaj, R. el Habib, S. Gurunathan, W. Heyward, D. Birx, J. McNeil, A. E. Brown; Thai AIDS Vaccine Evaluation Group, Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J. Infect. Dis. 190, 702-706 (2004).
9. M. J. McElrath, S. C. De Rosa, Z. Moodie, S. Dubey, L. Kierstead, H. Janes, O. D. Defawe, D. K. Carter, J. Hural, R. Akondy, S. P. Buchbinder, M. N. Robertson, D. V. Mehrotra, S. G. Self, L. Corey, J. W. Shiver, D. R. Casimiro; Step Study Protocol Team, HIV-1 vaccine-induced immunity in the test-of-concept Step Study: A case-cohort analysis. Lancet 372, 1894-1905 (2008).
10. P. Pitisuttithum, P. Gilbert, M. Gurwith, W. Heyward, M. Martin, F. van Griensven, D. Hu, J. W. Tappero, K. Choopanya; Bangkok Vaccine Evaluation Group, Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194, 1661-1671 (2006).
11. N. M. Flynn, D. N. Forthal, C. D. Harro, F. N. Judson, K. H. Mayer, M. F. Para; rgp120 HIV Vaccine Study Group, Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191, 654-665 (2005).
12. B. F. Haynes, P. B. Gilbert, M. J. McElrath, S. Zolla-Pazner, G. D. Tomaras, S. M. Alam, D. T. Evans, D. C. Montefiori, C. Karnasuta, R. Sutthent, H.-X. Liao, A. L. DeVico, G. K. Lewis, C. Williams, A. Pinter, Y. Fong, H. Janes, A. DeCamp, Y. Huang, M. Rao, E. Billings, N. Karasavvas, M. L. Robb, V. Ngauy, M. S. de Souza, R. Paris, G. Ferrari, R. T. Bailer, K. A. Soderberg, C. Andrews, P. W. Berman, N. Frahm, S. C. De Rosa, M. D. Alpert, N. L. Yates, X. Shen, R. A. Koup, P. Pitisuttithum, J. Kaewkungwal, S. Nitayaphan, S. Rerks-Ngarm, N. L. Michael, J. H. Kim, Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275-1286 (2012).
13. D. C. Montefiori, C. Karnasuta, Y. Huang, H. Ahmed, P. Gilbert, M. S. de Souza, R. McLinden, S. Tovanabutra, A. Laurence-Chenine, E. Sanders-Buell, M. A. Moody, M. Bonsignori, C. Ochsenbauer, J. Kappes, H. Tang, K. Greene, H. Gao, C. C. LaBranche, C. Andrews, V. R. Polonis, S. Rerks-Ngarm, P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, S. G. Self, P. W. Berman, D. Francis, F. Sinangil, C. Lee, J. Tartaglia, M. L. Robb, B. F. Haynes, N. L. Michael, J. H. Kim, Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J. Infect. Dis. 206, 431-441 (2012).
14. N. Karasavvas, E. Billings, M. Rao, C. Williams, S. Zolla-Pazner, R. T. Bailer, R. A. Koup, S. Madnote, D. Arworn, X. Shen, G. D. Tomaras, J. R. Currier, M. Jiang, C. Magaret, C. Andrews, R. Gottardo, P. Gilbert, T. J. Cardozo, S. Rerks-Ngarm, S. Nitayaphan, P. Pitisuttithum, J. Kaewkungwal, R. Paris, K. Greene, H. Gao, S. Gurunathan, J. Tartaglia, F. Sinangil, B. T. Korber, D. C. Montefiori, J. R. Mascola, M. L. Robb, B. F. Haynes, V. Ngauy, N. L. Michael, J. H. Kim, M. S. de Souza; MOPH TAVEG Collaboration, The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res. Hum. Retroviruses 28, 1444-1457 (2012).
15. R. Gottardo, R. T. Bailer, B. T. Korber, S. Gnanakaran, J. Phillips, X. Shen, G. D. Tomaras, E. Turk, G. Imholte, L. Eckler, H. Wenschuh, J. Zerweck, K. Greene, H. Gao, P. W. Berman, D. Francis, F. Sinangil, C. Lee, S. Nitayaphan, S. Rerks-Ngarm, J. Kaewkungwal, P. Pitisuttithum, J. Tartaglia, M. L. Robb, N. L. Michael, J. H. Kim, S. Zolla-Pazner, B. F. Haynes, J. R. Mascola, S. Self, P. Gilbert, D. C. Montefiori, Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLOS One 8, e75665 (2013).
16. S. M. Alam, H.-X. Liao, G. D. Tomaras, M. Bonsignori, C.-Y. Tsao, K.-K. Hwang, H. Chen, K. E. Lloyd, C. Bowman, L. Sutherland, T. L. Jeffries Jr., D. M. Kozink, S. Stewart, K. Anasti, F. H. Jaeger, R. Parks, N. L. Yates, R. G. Overman, F. Sinangil, P. W. Berman, P. Pitisuttithum, J. Kaewkungwal, S. Nitayaphan, N. Karasavva, S. Rerks-Ngarm, J. H. Kim, N. L. Michael, S. Zolla-Pazner, S. Santra, N. L. Letvin, S. C. Harrison, B. F. Haynes, Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. J. Virol. 87, 1554-1568 (2013).
17. S. Zolla-Pazner, A. deCamp, P. B. Gilbert, C. Williams, N. L. Yates, W. T. Williams, R. Howington, Y. Fong, D. E. Morris, K. A. Soderberg, C. Irene, C. Reichman, A. Pinter, R. Parks, P. Pitisuttithum, J. Kaewkungwal, S. Rerks-Ngarm, S. Nitayaphan, C. Andrews, R. J. O'Connell, Z. Y. Yang, G. J. Nabel, J. H. Kim, N. L. Michael, D. C. Montefiori, H. X. Liao, B. F. Haynes, G. D. Tomaras, Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLOS One 9, e87572 (2014).
18. J. Pollara, M. Bonsignori, M. A. Moody, P. Liu, S. M. Alam, K.-K. Hwang, T. C. Gurley, D. M. Kozink, L. C. Armand, D. J. Marshall, J. F. Whitesides, J. Kaewkungwal, S. Nitayaphan, P. Pitisuttithum, S. Rerks-Ngarm, M. L. Robb, R. J. O'Connell, J. H. Kim, N. L. Michael, D. C. Montefiori, G. D. Tomaras, H.-X. Liao, B. F. Haynes, G. Ferrari, HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. J. Virol. 88, 7715-7726 (2014).
19. S. S. Li, P. B. Gilbert, G. D. Tomaras, G. Kijak, G. Ferrari, R. Thomas, C.-W. Pyo, S. Zolla-Pazner, D. Montefiori, H.-X. Liao, G. Nabel, A. Pinter, D. T. Evans, R. Gottardo, J. Y. Dai, H. Janes, D. Morris, Y. Fong, P. T. Edlefsen, F. Li, N. Frahm, M. D. Alpert, H. Prentice, S. Rerks-Ngarm, P. Pitisuttithum, J. Kaewkungwal, S. Nitayaphan, M. L. Robb, R. J. O'Connell, B. F. Haynes, N. L. Michael, J. H. Kim, M. J. McElrath, D. E. Geraghty, FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. J. Clin. Invest. 124, 3879-3890 (2014).
20. H.-X. Liao, M. Bonsignori, S. M. Alam, J. S. McLellan, G. D. Tomaras, M. A. Moody, D. M. Kozink, K.-K. Hwang, X. Chen, C.-Y. Tsao, P. Liu, X. Lu, R. J. Parks, D. C. Montefiori, G. Ferrari, J. Pollara, M. Rao, K. K. Peachman, S. Santra, N. L. Letvin, N. Karasavvas, Z.-Y. Yang, K. Dai, M. Pancera, J. Gorman, K. Wiehe, N. I. Nicely, S. Rerks-Ngarm, S. Nitayaphan, J. Kaewkungwal, P. Pitisuttithum, J. Tartaglia, F. Sinangil, J. H. Kim, N. L. Michael, T. B. Kepler, P. D. Kwong, J. R. Mascola, G. J. Nabel, A. Pinter, S. Zolla-Pazner, B. F. Haynes, Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38, 176-186 (2013).
21. K. Wiehe, D. Easterhoff, K. Luo, N. I. Nicely, T. Bradley, F. H. Jaeger, S. M. Dennison, R. Zhang, K. E. Lloyd, C. Stolarchuk, R. Parks, L. L. Sutherland, R. M. Scearce, L. Morris, J. Kaewkungwal, S. Nitayaphan, P. Pitisuttithum, S. Rerks-Ngarm, F. Sinangil, S. Phogat, N. L. Michael, J. H. Kim, G. Kelsoe, D. C. Montefiori, G. D. Tomaras, M. Bonsignori, S. Santra, T. B. Kepler, S. M. Alam, M. A. Moody, H.-X. Liao, B. F. Haynes, Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. Immunity 41, 909-918 (2014).
22. S. M. Hammer, M. E. Sobieszczyk, H. Janes, S. T. Karuna, M. J. Mulligan, D. Grove, B. A. Koblin, S. P. Buchbinder, M. C. Keefer, G. D. Tomaras, N. Frahm, J. Hural, C. Anude, B. S. Graham, M. E. Enama, E. Adams, E. DeJesus, R. M. Novak, I. Frank, C. Bentley, S. Ramirez, R. Fu, R. A. Koup, J. R. Mascola, G. J. Nabel, D. C. Montefiori, J. Kublin, M. J. McElrath, L. Corey, P. B. Gilbert; HVTN 505 Study Team, Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N. Engl. J. Med. 369, 2083-2092 (2013).
23. M. Rolland, P. T. Edlefsen, B. B. Larsen, S. Tovanabutra, E. Sanders-Buell, T. Hertz, A. C. deCamp, C. Carrico, S. Menis, C. A. Magaret, H. Ahmed, M. Juraska, L. Chen, P. Konopa, S. Nariya, J. N. Stoddard, K. Wong, H. Zhao, W. Deng, B. S. Maust, M. Bose, S. Howell, A. Bates, M. Lazzaro, A. O'Sullivan, E. Lei, A. Bradfield, G. Ibitamuno, V. Assawadarachai, R. J. O'Connell, M. S. deSouza, S. Nitayaphan, S. Rerks-Ngarm, M. L. Robb, J. S. McLellan, I. Georgiev, P. D. Kwong, J. M. Carlson, N. L. Michael, W. R. Schief, P. B. Gilbert, J. I. Mullins, J. H. Kim, Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 490, 417-420 (2012).
24. S. Zolla-Pazner, P. T. Edlefsen, M. Rolland, X.-P. Kong, A. deCamp, R. Gottardo, C. Williams, S. Tovanabutra, S. Sharpe-Cohen, J. I. Mullins, M. S. deSouza, N. Karasavvas, S. Nitayaphan, S. Rerks-Ngarm, P. Pitisuttihum, J. Kaewkungwal, R. J. O'Connell, M. L. Robb, N. L. Michael, J. H. Kim, P. Gilbert, Vaccine-induced human antibodies specific for the third variable region of HIV-1 gp120 impose immune pressure on infecting viruses. EBioMedicine 1, 37-45 (2014).
25. S. Zolla-Pazner, X.-P. Kong, X. Jiang, T. Cardozo, A. Nádas, S. Cohen, M. Totrov, M. S. Seaman, S. Wang, S. Lu, Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA. J. Virol. 85, 9887-9898 (2011).
26. G. D. Tomaras, B. F. Haynes, HIV-1-specific antibody responses during acute and chronic HIV-1 infection. Curr. Opin. HIV AIDS 4, 373-379 (2009).
27. N. L. Yates, H.-X. Liao, Y. Fong, A. deCamp, N. A. Vandergrift, W. T. Williams, S. M. Alam, G. Ferrari, Z.-. Yang, K. E. Seaton, P. W. Berman, M. D. Alpert, D. T. Evans, R. J. O'Connell, D. Francis, F. Sinangil, C. Lee, S. Nitayaphan, S. Rerks-Ngarm, J. Kaewkungwal, P. Pitisuttithum, J. Tartaglia, A. Pinter, S. Zolla-Pazner, P. B. Gilbert, G. J. Nabel, N. L. Michael, J. H. Kim, D. C. Montefiori, B. F. Haynes, G. D. Tomaras, Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 in fection risk and declines soon after vaccination. Sci. Transl. Med. 6, 228ra239 (2014).
28. A. W. Chung, M. Ghebremichael, H. Robinson, E. Brown, I. Choi, S. Lane, A.-S. Dugast, M. K. Schoen, M. Rolland, T. J. Suscovich, A. E. Mahan, L. Liao, H. Streeck, C. Andrews, S. Rerks-Ngarm, S. Nitayaphan, M. S. de Souza, J. Kaewkungwal, P. Pitisuttithum, D. Francis, N. L. Michael, J. H. Kim, C. Bailey-Kellogg, M. E. Ackerman, G. Alter, Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci. Transl. Med. 6, 228ra238 (2014).
29. M. Bonsignori, J. Pollara, M. A. Moody, M. D. Alpert, X. Chen, K.-K. Hwang, P. B. Gilbert, Y. Huang, T. C. Gurley, D. M. Kozink, D. J. Marshall, J. F. Whitesides, C.-Y. Tsao, J. Kaewkungwal, S. Nitayaphan, P. Pitisuttithum, S. Rerks-Ngarm, J. H. Kim, N. L Michael, G. D. Tomaras, D. C. Montefiori, G. K. Lewis, A. DeVico, D. T. Evans, G. Ferrari, H.-X. Liao, B. F. Haynes, Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J. Virol. 86, 11521-11532 (2012).
30. G. D. Tomaras, G. Ferrari, X. Shen, S. M. Alam, H.-X. Liao, J. Pollara, M. Bonsignori, M. A. Moody, Y. Fong, X. Chen, B. Poling, C. O. Nicholson, R. Zhang, X. Lu, R. Parks, J. Kaewkungwal, S. Nitayaphan, P. Pitisuttithum, S. Rerks-Ngarm, P. B. Gilbert, J. H. Kim, N. L. Michael, D. C. Montefiori, B. F. Haynes, Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc. Natl. Acad. Sci. U.S.A. 110, 9019-9024 (2013).
31. A. J. Hessell, L. Hangartner, M. Hunter, C E. Havenith, F.J. Beurskens, J. M. Bakker, C M. Lanigan, G. Landucci, D. N. Forthal, P. W. Parren, P. A. Marx, D. R. Burton, Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449, 101-104 (2007).
32. A. J. Smith, S. W. Wietgrefe, L. Shang, C S. Reilly, P. J. Southern, K. E. Perkey, L. Duan, H. Kohler, S. Müller, J. Robinson, J. V. Carlis, Q. Li, R. P.Johnson, A. T. Haase, Live simian immunodeficiency virus vaccine correlate of protection: Immune complex-inhibitory Fc receptor interactions that reduce target cell availability. J. Immunol. 193, 3126-3133 (2014).
33. S.-Y. Ko, A. Pegu, R. S. Rudicell, Z.-. Yang, M. G. Joyce, X. Chen, K. Wang, S. Bao, T. D. Kraemer, T. Rath, M. Zeng, S. D. Schmidt, J.-P. Todd, S. R. Penzak, K. O. Saunders, M. C. Nason, A. T. Haase, S. S. Rao, R. S. Blumberg, J. R. Mascola, G. J. Nabel, Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514, 642-645 (2014).
34. R. Lassauniere, C. T. Tiemessen, Fcy receptor variability in the South African population-Will this impact on HVTN097 and vaccine efficacy? AIDS Res. Hum. Retroviruses 30, A219 (2014).
35. A. Pegu, Z.-. Yang, J. C. Boyington, L. Wu, S.-Y. Ko, S. D. Schmidt, K. McKee, W.-P. Kong, W. Shi, X. Chen, J.-P. Todd, N. L. Letvin, J. Huang, M. C. Nason, J. A. Hoxie, P. D. Kwong, M. Connors, S. S. Rao, J. R. Mascola, G. J. Nabel, Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci. Transl. Med. 6, 243ra288 (2014).
36. mac251 challenge. J. Immunol. 177, 4028-4036 (2006).
37. J. M. Binley, B. Clas, A. Gettie, M. Vesanen, D. C. Montefiori, L. Sawyer, J. Booth, M. Lewis, P. A. Marx, S. Bonhoeffer, J. P. Moore, Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia. Virology 270, 237-249 (2000).
38. M. Asmal, C. Luedemann, C L. Lavine, LV. Mach, H. Balachandran, C Brinkley, T. N. Denny, M. G. Lewis, H. Anderson, R. Pal, D.Sok, K. Le, M. Pauthner, B. H. Hahn, G. M. Shaw, M. S. Seaman, N. L. Letvin, D. R. Burton, J. G. Sodroski, B. F. Haynes, S. Santra, Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes. Virology 475, 37-45 (2015).
39. H.-W. Chang, L. J. Tartaglia, J. B.Whitney, S.-Y. Lim, S. Sanisetty, C. L. Lavine, M. S. Seaman, C. Rademeyer, C. Williamson, K. Ellingson-Strouss, L. Stamatatos, J. Kublin, D. H. Barouch, Generation and evaluation of clade C simian-human immunodeficiency virus challenge stocks. J. Virol. 89, 1965-1974 (2015).
40. L. Lin, G. Finak, K. Ushey, C. Seshadri, T. R. Hawn, N. Frahm, T. J. Scriba, H. Mahomed, W. Hanekom, P.-A. Bart, G. Pantaleo, G. D. Tomaras, S. Rerks-Ngarm, J. Kaewkungwal, S. Nitayaphan, P. Pitisuttithum, N. L Michael, J. H. Kim, M. L. Robb, R. J. O'Connell, N. Karasavvas, P. Gilbert, S. C. De Rosa, M. J. McElrath, R. Gottardo, COMPASS identifies T-cell subsets correlated with clinical outcomes. Nat. Biotechnol. 33, 610-616 (2015).
41. L. Lin, G. Finak, K. Ushey, C. Seshadri, T. Hawn, N. Frshm, T. Scriba, H. Mahomed, E. Hanekom, P. Bart, G. Pantaleo, G. Tomaras, S. Rerks-Ngarm, J. Kaewkungwal, S. Nitayaphan, P. Pitisuttithum, N. Michael, J. Kim, M. Robb, R. O'Connell, N. Karasavvas, P. Gilbert, S. DeRosa, M. McElrath, R. Gottardo, Combinatorial polyfunctionality analysis of antigen-specific T-cell subsets identified novel cellular subsets correlated with clinical outcomes. Nat. Biotechnol., in press.
42. Recommendations for the Future Utility of the RV144 Vaccines to the Thai Ministry of Health (Global HIV Vaccine Enterprise, WHO-UNAIDS, Thai Ministry of Public, U.S. Military HIV Research Program, Bangkok, 2010).
43. D. H. Barouch, J. Liu, H. Li, L. F. Maxfield, P. Abbink, D. M. Lynch, M. J. Iampietro, A. SanMiguel, M. S. Seaman, G. Ferrari, D. N. Forthal, I. Ourmanov, V. M. Hirsch, A. Carville, K. G. Mansfield, D. Stablein, M. G. Pau, H. Schuitemaker, J. C. Sadoff, E. A. Billings, M. Rao, L. Robb, J. H. Kim, M. A. Marovich, J. Goudsmit, N. L. Michael, Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482, 89-93 (2012).
44. D. H. Barouch, G. Alter, T. Broge, C. Linde, M. E. Ackerman, E. P. Brown, E. N. Borducchi, K. M.Smith, J. P. Nkolola, J. Liu, J.Shields, L. Parenteau, J. B.Whitney, P. Abbink, D. M. Ng'ang'a, M.S.Seaman, C. L. Lavine, J.R.Perry, W.Li, A. D.Colantonio, M.G. Lewis, B.Chen, H.Wenschuh, U. Reimer, M. Piatak, J. D. Lifson, S. A. Handley, H. W. Virgin, M. Koutsoukos, C. Lorin, G. Voss, M. Weijtens, M. G. Pau, H. Schuitemaker, Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science 349, 320-324 (2015).
45. D. H. Barouch, K. E. Stephenson, E. N. Borducchi, K. Smith, K. Stanley, A. G. McNally, J. Liu, P. Abbink, L. F. Maxfield, M. S. Seaman, A.-S. Dugast, G. Alter, M. Ferguson, W. Li, P. L. Earl, B. Moss, E. E. Giorgi, J. J. Szinger, L. A. Eller, E. A. Billings, M. Rao, S. Tovanabutra, E. Sanders-Buell, M. Weijtens, M. G. Pau, H. Schuitemaker, M. L. Robb, J. H. Kim, B. T. Korber, N. L. Michael, Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 155, 531-539 (2013).
46. L. Corey, G. J. Nabel, C. Dieffenbach, P. Gilbert, B. F. Haynes, M. Johnston, J. Kublin, H. C. Lane, G. Pantaleo, L. J. Picker, A. S. Fauci, HIV-1 vaccines and adaptive trial designs. Sci. Transl. Med. 3, 79ps13 (2011).
47. P. Gilbert, D. Grove, A sequential two-stage trial design for evaluating efficacy and immune correlates for multiple vaccine regimens. HVTNews 3, 2-4 (2011).
48. M. Singh, M. Ugozzoli, J. Kazzaz, J. Chesko, E. Soenawan, D. Mannucci, F. Titta, M. Contorni, G. Volpini, G. Del Guidice, D. T. O'Hagan, A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine 24, 1680-1686 (2006).
49. H. Lal, A. L. Cunningham, O. Godeaux, R. Chlibek, J. Diez-Domingo, S.-J. Hwang, M. J. Levin, J. E. McElhaney, A. Poder, J. Puig-Barberà, T. Vesikari, D. Watanabe, L. Weckx, T. Zahaf, T. C. Heineman; ZOE-50 Study Group, Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N. Engl. J. Med. 372, 2087-2096 (2015).
50. J. G. Jardine, T. Ota, D. Sok, M. Pauthner, D. W. Kulp, O. Kalyuzhniy, P. D. Skog, T. C. Thinnes, D. Bhullar, B. Briney, S. Menis, M. Jones, M. Kubitz, S. Spencer, Y. Adachi, D. R. Burton, W. R. Schief, D. Nemazee, Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 349, 156-161 (2015).
51. P.-A. Bart, R. Goodall, T. Barber, A. Harari, A. Guimaraes-Walker, M. Khonkarly, N. C. Sheppard, Y. Bangala, M.-J. Frachette, R. Wagner, P. Liljeström, J.-P. Kraehenbuhl, M. Girard, J. Goudsmit, M. Esteban, J. Heeney, Q. Sattentau, S. McCormack, A. Babiker, G. Pantaleo, J. Weber; EuroVacc Consortium, EV01: A phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine 26, 3153-3161 (2008).
52. G. Pantaleo, M. Esteban, B. Jacobs, J. Tartaglia, Poxvirus vector-based HIV vaccines. Curr. Opin. HIV AIDS 5, 391-396 (2010).
53. J. A. Johnson, D. H. Barouch, L. R. Baden, Nonreplicating vectors in HIV vaccines. Curr. Opin. HIV AIDS 8, 412-420 (2013).
54. B. F. Haynes, L. Verkoczy, Host controls of HIV neutralizing antibodies. Science 344, 588-589 (2014).
55. R. W. Sanders, M. J. van Gils, R. Derking, D. Sok, T. J. Ketas, J. A. Burger, G. Ozorowski, A. Cupo, C. Simonich, L. Goo, H. Arendt, H. J. Kim, J. H. Lee, P. Pugach, M. Williams, G. Debnath, B. Moldt, M. J. van Breemen, G. Isik, M. Medina-Ramírez, J. W. Back, W. C. Koff, J.-P. Julien, E. G. Rakasz, M. S. Seaman, M. Guttman, K. K. Lee, P. J. Klasse, C. LaBranche, W. R. Schief, I. A. Wilson, J. Overbaugh, D. R. Burton, A. B. Ward, D. C. Montefiori, H. Dean, J. P. Moore, HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science 349, aac4223 (2015).
56. J. Chen, J. M. Kovacs, H. Peng, S. Rits-Volloch, J. Lu, D. Park, E. Zablowsky, M. S. Seaman, B. Chen, Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein. Science 349, 191-195 (2015).
57. X. Wu, Z.-Y. Yang, Y. Li, C.-M. Hogerkorp, W. R. Schief, M. S. Seaman, T. Zhou, S. D. Schmidt, L. Wu, L. Xu, N. S. Longo, K. McKee, S. O'Dell, M. K. Louder, D. L. Wycuff, Y. Feng, M. Nason, N. Doria-Rose, M. Connors, P. D. Kwong, M. Roederer, R. T. Wyatt, G. J. Nabel, J. R. Mascola, Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861 (2010).
58. Y. Li, S. O'Dell, L. M. Walker, X. Wu, J. Guenaga, Y. Feng, S. D. Schmidt, K. McKee, M. K. Louder, J. E. Ledgerwood, B. S. Graham, B. F. Haynes, D. R. Burton, R. T. Wyatt, J. R. Mascola, Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J. Virol. 85, 8954-8967 (2011).
59. G. K. Lewis, A. L. DeVico, R. C. Gallo, Antibody persistence and T-cell balance: Two key factors confronting HIV vaccine development. Proc. Natl. Acad. Sci. U.S.A. 111, 15614-15621 (2014).